[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.75.176. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 656
Citations 0
Correction
April 10, 2013

Incorrect Number in Figure in: Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure: The ASTRONAUT Randomized Trial

JAMA. 2013;309(14):1461. doi:10.1001/jama.2013.3309

Incorrect Number in Figure: In the Original Contribution entitled, “Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure: The ASTRONAUT Randomized Trial,” published in the March 20, 2013, issue of JAMA (2013;309[11]:1125-1135), one of the values in Figure 1 was incorrect. In the box describing the primary efficacy phase (to death or 6 months), the second line should have read “13 Did not complete, vital status unknown, or GCP violation.” The article has been corrected online.

×